Questionnaire-4700018541-Pyloshot as adjuvantMCI Registration NumberFULL NAME (As in your Pancard)EmailPhone/MobileCityStateSpecialityBank DetailsAccount Holder NameA/c NumberIFSC CodeUpload Cancelled Cheque (Max Size - 2 MB)Choose File Pancard NumberUpload Pancard Details (Max Size - 2 MB)Choose File Clinical Insight Mapping: “Postbiotic(Lactobacillus Reuteri DSM 17648) as an Adjuvant to Standard Helicobacter pylori Infection Eradication Therapy: Evaluating Impact on Antibiotic Resistance & Long-Term Gastric Outcomes”1. Approximately how many Helicobacter pylori Infection patients do you manage in a month? More than 50 patients 30–50 patients 10–30 patients Less than 10 patients2. Approximately what percentage of your H. pylori eradication failures do you attribute to antibiotic resistance? More than 75% of failures 50–75% of failures 25–50% of failures Less than 25% of failures3. Which patient profile most commonly raises suspicion of persistent/refractory H. pylori infection? Recurrent gastritis symptoms Repeated dyspepsia despite therapy History of multiple antibiotic exposure Recurrent peptic ulcer disease4. Do you consider antibiotic resistance as the primary contributor to H. pylori eradication failure today? Yes No5. What is your preferred first-line strategy for H. pylori eradication? Triple therapy Quadruple therapy Culture-guided therapy Sequential/concomitant therapy6. How often do you encounter gastrointestinal side effects leading to poor compliance during eradication therapy? Frequently Occasionally Rarely Almost never7. Which long-term complication concerns you most in inadequately treated H. pylori infection? Chronic gastritis progression Peptic ulcer recurrence Gastric mucosal damage/atrophy Gastric malignancy risk8. In your opinion, what defines successful long-term management after H. pylori eradication? Sustained symptom relief Prevention of recurrence Gastric mucosal healing Reduced future gastric complications9. What potential benefit do you most expect from adding postbiotic-Lactobacillus reuteri DSM 17648 as an adjunct to standard eradication therapy? Improved eradication success Reduction in antibiotic-associated side effects Better gastric mucosal recovery Reduced recurrence/reinfection risk10. Do you believe adjunctive support with postbiotic-Lactobacillus reuteri DSM 17648 can help address challenges associated with antibiotic resistance? Strongly agree Agree to some extent Minimal impact No significant role11. In which patient group would you most strongly consider adding postbiotic-Lactobacillus reuteri DSM 17648 support? Recurrent/refractory H. pylori cases Patients with antibiotic intolerance Chronic gastritis with mucosal damage All patients receiving eradication therapy12. How likely are you to adopt postbiotic-Lactobacillus reuteri DSM 17648-supportive adjunctive therapies in future H. pylori management? Highly likely Moderately likely Neutral Unlikely I have read and agree to the Terms and Conditions .Submit Form